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ABSTRACT
Background: Patients with myotonic dystrophy type 1 (DM1) frequently have symptoms of exces-
sive daytime sleepiness (EDS). Some patients with DM1 show sleep-onset REM, similar to that
observed in narcolepsy. Narcolepsy is characterized by impaired hypocretin (Hcrt) neurotransmis-
sion.
Objective: To test for dysregulation of Hcrt neurotransmission in a prospective cohort of patients
with DM1.
Methods: Hcrt levels in CSF were measured by radioimmunoassay. Sleep physiology was as-
sessed by overnight polysomnography (PSG) and a multiple sleep latency test (MSLT). Splicing of
Hcrt receptor 1 and 2 (HcrtR1 and HcrtR2) mRNA was examined in postmortem samples of tem-
poral cortex.
Results: Seventeen of 38 patients with DM1 reported symptoms of EDS. Among patients with
DM1 with EDS who underwent PSG/MSLT, 7 of 13 showed reduced sleep latency, sleep-onset
REM, or both. However, CSF Hcrt levels in DM1 (mean 277 pg/mL, n  38) were not different
from controls (mean 277 pg/mL, n  33). Also, splicing of HcrtR1 and HcrtR2 mRNA in patients
with DM1 was similar to controls.
Conclusions: Excessive daytime sleepiness and dysregulation of REM sleep occur frequently in
patients with myotonic dystrophy type 1 (DM1). However, the pathophysiologic basis is distinct
from narcolepsy, as patients with DM1do not have a consistent defect of Hcrt release or receptor
splicing. Neurology® 2008;70:226–230
GLOSSARY
AHI  apnea/hypopnea index; DM1  myotonic dystrophy type 1; EDS  excessive daytime sleepiness; ESS  Epworth
Sleepiness Scale; Hcrt  hypocretin; MIRS  Muscular Impairment Rating Scale; MSL  mean sleep latency; MSLT 
multiple sleep latency test; PLM periodic limb movement; PSG polysomnography; SL sleep onset latency; SOREMP
sleep onset REM periods; UM University of Milan, Italy; URMC University of Rochester Medical Center.
Myotonic dystrophy type 1 (DM1) is caused by expansion of a CTG repeat in the 3= untrans-
lated region of the DMPK gene on chromosome 19. The mutant RNA forms ribonuclear
inclusions,1 sequesters splicing factors in the muscleblind family,2 and interferes with regu-
lated alternative splicing of pre-mRNA.3 For example, myotonia in DM1 is associated with
misregulated alternative splicing of the ClC-1 chloride channel.4,5 A similar RNA-mediated
disease process may underlie CNS symptoms of DM1.6,7 Toxicity of expanded repeat RNA
has also been implicated in other neurodegenerative disorders.8,9
Excessive daytime sleepiness (EDS) is a common and disabling feature of DM1.10-12
However, the pathophysiology of the sleep disturbance is poorly understood. In some
individuals with advanced disease, EDS may result from effects of DM1 on oropharyn-
geal and respiratory muscles, leading to obstructive sleep apnea and nocturnal hypoven-
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tilation.13,14 Several lines of evidence
suggest that DM1 may also have direct ef-
fects on sleep regulatory circuits in the
CNS.15-22
Narcolepsy is associated with decreased
levels of hypocretin 1 (Hcrt-1) in the CSF and
loss of Hcrt-1-releasing neurons in the dorso-
lateral hypothalamus.23 Hereditary narco-
lepsy in dogs is caused by mutations that
affect splicing in the hypocretin receptor 2
(HcrtR2) gene.24 Recently it was reported
that Hcrt-1 was reduced in CSF in patients
with DM125 and that sleep onset REM, simi-
lar to that observed in narcolepsy, was ob-
served in patients with DM1.15,16 To
determine if DM1 is associated with abnor-
mal Hcrt-1 action, we carried out a prospec-
tive study of CSF Hcrt-1 in patients with
DM1who did or did not have EDS.
METHODS Study participants. Our cohort consisted
of 38 patients with genetically confirmed DM1. Fifteen sub-
jects were women and 23 were men (mean age 43 years,
range 24 to 72 years). Twenty-five patients were enrolled at
the University of Milan, Italy (UM), and 13 patients were
enrolled at the University of Rochester Medical Center
(URMC). The study was approved by respective Institu-
tional Review Boards in both centers, and informed consent
was obtained from all participants. Patients were excluded if
they had contraindication for lumbar puncture, evidence for
major respiratory involvement (vital capacity 60% of pre-
dicted), advanced muscle weakness (inability to walk 30 feet
independently), congenital myotonic dystrophy, and use of
medications known to affect wakefulness or sleep. Patients
with a prior diagnosis of major depression, sleep apnea, or
using nocturnal bilevel positive airway pressure system or
CPAP were also excluded because of the EDS and altered
sleep architecture that can occur in such patients. The dura-
tion of DM1 symptoms in our cohort ranged from 6 to 25
years. Muscle weakness ranged from mild to moderate
(Muscular Impairment Rating Scale [MIRS] 2, 3, 4, and 5).26
Demographic characteristics, ESS, andMIRS did not dif-
fer between the UM and URMC patients. Patients were in-
terview screened for cataplexy.
Symptoms of sleepiness were assessed using the Epworth
Sleepiness Scale (ESS), an 8-item self-reported questionnaire
with a possible score ranging from 0 to 24.27
A t test was used for comparison between groups.
Hcrt-1 assays. Lumbar puncture was performed in the
morning and CSF was immediately stored at80 °C. Hcrt-1
levels were measured at the Stanford Center for Narcolepsy
using a direct radioimmunoassay with I125-labeled Hcrt-1 as
previously described.23 The CSF Hcrt-1 values in patients
with DM1 were compared with 33 non-DM1 controls who
did not have symptoms of a sleep disorder. The presence of
HLA DQB1*0602 was determined using previously estab-
lished PCR assays in the 13 URMC patients.23
Evaluation of daytime sleepiness and sleep-related
breathing disorders. In addition to lumbar puncture, 13
URMC patients underwent overnight polysomnography
(PSG) followed by a Multiple Sleep Latency Test (MSLT).
Sleep scoring. PSGswere scored in 30-second epochs accord-
ing to Rechtschaffen and Kales criteria.28 PSG scorers identified
apnea/hypopnea and periodic limb movement (PLM) events
based on standard criteria (American Academy of Sleep Medi-
cine guidelines).29 These events were tabulated to form an ap-
nea/hypopnea index (AHI) and PLM index. A complete
description of recording and scoring for the polysomnogram
andMSLT is provided in the supplemental methods section on
theNeurology®Web site at www.neurology.org.
MSLT. This procedure was performed on the day follow-
ing the PSG utilizing a four-nap protocol beginning no later
than 10 AM and interspersed by 2-hour intervals. Standard
procedures were used as specified by Carskadon et al.30,31 A
mean sleep latency (MSL) value from the four sessions was
calculated for each patient. The number of sleep-onset REM
periods during the study was determined.
Analysis of Hcrt receptor (HcrtR) splicing. We exam-
ined splicing of HcrtR1 and HcrtR2 transcripts in RNA iso-
lated from temporal cortex of two patients with DM1, one
control with Huntington disease, and one control with no
neurologic disease. Neither patient with DM1 had partici-
pated in the CSF Hcrt-1 study, but both had reported symp-
toms of excessive sleepiness. HcrtR1, HcrtR2, and DMPK
are all expressed in temporal cortex. The cortical tissue was
dissected at the time of autopsy, flash frozen in liquid nitro-
gen, and then stored at 70 °C. We selected DM1 samples
that previously had clearly shown misregulated alternative
splicing, as determined by splicing of tau, amyloid precursor
protein, and NMDA receptor 1.6 We screened the entire cod-
ing sequence of each receptor in two overlapping RT-PCR
products (707 or 785 bp length). These products were ana-
lyzed on laser-scanned agarose gels as described.2 To test for
splicing alterations having a small effect on the size of HcrtR
cDNAs, we also analyzed each RT-PCR product after diges-
tion with several different restriction enzymes (TaqI, AluI,
DpnII,NlaIII, BglI, AlwNI, or AflII).
RESULTS Hcrt-1 levels in CSF. CSF Hcrt-1 levels
in 38 patients with DM1 (mean 277 pg/mL, range
176 to 448 pg/mL) did not differ from 33 controls
(mean 277 pg/mL, range 186 to 382 pg/mL) (figure
1). The mean ESS score in 38 patients with DM1
was 10.4 (range 3 to 24). ESS scores greater than
10 are generally taken to reflect abnormal day-
time sleepiness.27 No significant difference in
Hcrt-1 level was found between the patients with an
ESS  10 (n  17; mean Hcrt-1 level 268 pg/mL;
mean ESS 15.4) as compared to those having an ESS
 10 (n  21; mean Hcrt-1 284; mean ESS 6.4).
Three of the 13 URMC patients (23%) were HLA-
DQB1*0602 positive, a frequency that was similar
to the general population (12% to 35%). Of note,
neither ESS scores (p 0.68) nor Hcrt-1 levels (p
0.25) correlated with the length of the CTG expan-
sion in circulating blood cells (data not shown).
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Overnight polysomnography. Sleep-related breathing
disorders and periodic limb movements. Apnea, hy-
popnea, and periodic leg movements were not
prominent in subjects with DM1 (table e-1 on
the Neurology® Web site at www.neurology.
org). DM1 patients exhibited a mean AHI of
5.9 (normal  0 to 5; obstructive sleep apnea,
mild  5 to 20; moderate  20 to 40; severe
40). Five subjects had AHIs between 5 and 20.
The mean PLM index for the group was 7.2
with all subjects having a PLM index below 21.
Sleep continuity. When compared with nor-
mative values,32 the mean value for sleep onset la-
tency (SL) fell within the normal range in DM1
(mean DM1 18.7 minutes vs normal 15 to 20
minutes) but this mean was driven by a very high
SL in a single patient (no. 3; SL  141 minutes).
By removing this outlying datapoint, SL was re-
duced in subjects with DM1 (mean SL 8.5 min-
utes) compared to normative data. Additionally,
four patients had SL under 5 minutes (table e-1).
Total sleep time (mean DM1  359.9 minutes vs
normal  375 to 425 minutes) was normal, and
sleep efficiency (mean DM1  82.6 vs normal 
85 to 95%) was normal in all but three patients.
Sleep architecture. When compared with norma-
tive values,32 the DM1 group exhibited a normal
percentage of stage 1 sleep (DM1 6.1% vs normal
 2.5 to 7.5%) and stage 2 sleep (DM1 56.9% vs
normal 45 to 55%), whereas slowwave sleep was
reduced (DM1  6.4% vs normal  13 to 15%)
(table e-2). The percentage of REM sleep was ele-
vated in DM1 (DM1  30.5% vs normal  20 to
25%), with 9 of 13 patients exhibiting a REM%
above 30% (table). Finally, six patients had a REM
latency less than 70 minutes, and in one patient the
latency was less than 10 minutes (normal REM la-
tency is 75 to 85 minutes).
Multiple sleep latency test. The mean MSLT sleep
latency for patients with DM1 was 9.1, where a
mean of 8 minutes is considered to represent
pathologic sleepiness and means above 10 minutes
are considered normal.33,34 Seven subjects had mean
sleep latencies8minutes, four of these were under
5minutes, and three of the subjects with short laten-
cies also had two or more sleep onset REM periods
(SOREMPs) (table). Five subjects exhibited
SOREMPs. There was no trend for reduced Hcrt-1
in patients whose MSLT testing showed reduced
sleep latency or SOREMPs (figure 1).
Hcrt receptor splicing. Splicing of HcrtR1 and
HcrtR2 mRNA in patients with DM1was not dif-
ferent from controls. Representative gels for anal-
ysis for HcrtR2 are shown in figure 2.
DISCUSSION Several lines of evidence suggest
that DM1 may also have direct effects on sleep
regulatory circuits in the CNS: 1) EDS may occur
early in the disease process, when oropharyngeal
and respiratory muscles are relatively pre-
Figure 1 CSF Hcrt-1 levels in patients with DM1
(n 38), patients with DM1with
ESS 10 (n 17), patients with
DM1with multiple sleep latency
test evidence of SOREMP or SL 8
minutes (n 7), and controls
without a sleep disorder (n 33)
Hcrt-1  hypocretin 1; DM1  myotonic dystrophy type 1;
ESS  Epworth Sleepiness Scale; SOREMP  sleep onset
REM periods; SL sleep onset latency.
Table Hcrt-1 levels, percent of REM sleep on
PSG, and MSLT data in 13 patients
with myotonic dystrophy type 1
Patient
ID
Hcrt-1,
pg/mL
PSG,
% REM
MSLT
Mean SL SOREMP
1 274.4 33.2 3.0 2
2 240.6 11.3 20.0 0
3 233.3 36.3 19.0 0
4 231.7 12.6 7.6 1
5 257.7 30.6 18.4 1
6 198.2 33.4 10.3 0
7 266.8 27.6 9.9 0
8 242.5 34.8 6.8 2
9 226.3 38.5 8.0 0
10 267.3 29.0 8.3 0
11 304.6 37.9 1.5 4
12 214.4 31.9 4.0 0
13 303.0 39.7 1.8 0
Mean 250.8 30.5 9.1 0.8
SD 32.0 9.0 6.4 1.2
Hcrt-1 hypocretin 1; PSG polysomnography; MSLT
multiple sleep latency test; SL sleep onset latency;
SOREMP sleep onset REM periods.
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served15,16; 2) polysomnographic abnormalities in
DM1 do not consistently correlate with evidence
of sleep-disordered breathing17; 3) adequate treat-
ment of sleep-disordered breathing does not al-
ways improve EDS18,19; 4) pulsatile secretion of
cortisol and growth hormone is disrupted in
DM1, suggesting a general disturbance of hypo-
thalamic regulation and circadian rhythm20,21; and
5) central hypoventilation and hypersomnia were
correlated in some patients with DM1 with au-
topsy findings of neuronal loss in the reticular
formation and dorsal raphe.22
Based on previous observations of reduced
Hcrt-125 and SOREMP in patients with DM1,15,16
we postulated that EDS in DM1 may result from
decreased Hcrt-1 release or misregulated Hcrt re-
ceptor splicing. Against our hypothesis, we found
that none of 38 patients with DM1 in our cohort
showed Hcrt-1 reductions in a range that is typi-
cally associated with narcolepsy (below 110
pg/mL in CSF).23 Indeed, the mean level of Hcrt-1
in patients with DM1 was identical to controls,
and Hcrt-1 levels in CSF showed no trend for re-
duction even among patients with DM1 who re-
ported symptoms of EDS or displayed MSLT
evidence for reduced sleep latency or SOREMPs.
Our cohort did include individuals whose EDS was
severe. For example, Patient 11 in the table was
given a diagnosis of narcolepsy many years prior to
the diagnosis of DM1, due to her severe hypersom-
nolence (ESS 16). Her MSLTmet criteria for narco-
lepsy yet her Hcrt-1 level was 304.6 pg/mL.
Furthermore, we found no abnormality of splicing
for Hcrt receptors 1 or 2, even in DM1 samples that
clearly showed spliceopathy for other transcripts.
Results of the present study differ from a pre-
vious study of six patients with DM1, in which
one patient had Hcrt-1 levels below110 pg/mL in
CSF, and three patients had Hcrt-1 levels between
110 and 200 pg/mL,25 a range that is intermediate
between levels observed in normal individuals
and patients with narcolepsy.23 By contrast, only
3 of 38 patients with DM1 in the current study, as
compared to 2 of 33 controls, had levels in this
intermediate range. As Hcrt-1 measurements for
both studies were carried out by the same meth-
ods in the same laboratory, it is unlikely that tech-
nical factors related to assay performance can
account for this difference. More likely, this dis-
parity relates to differences in patient selection or
methods of CSF collection, storage, or transport.
Results of our study confirm that DM1 is associ-
ated with SOREMPs. In particular, several of our
patients had short mean sleep latencies across all
four naps in the MSLT study, five had SOREMPs,
and two patients had mean sleep latency 5 min-
utes and2 SOREMPs. These results are similar to
previous retrospective analyses.15,16 SOREMPs are a
characteristic feature of narcolepsy. Our patients
with DM1 did not report symptoms of cataplexy;
however, the physiologic and anatomic substrates
of REM intrusion and cataplexy components are
separable.35 PSG data in patients with narcolepsy is
typified by low sleep efficiency, frequent awaken-
ings, REM sleep fragmentation, and increased per-
centage of stage 1 sleep. By contrast, a novel finding
in our study was that patients with DM1 displayed
increased REM sleep rather than stage 1 sleep.
These results support the idea that hypersomno-
lence in DM1 may result from an intrinsic CNS de-
fect that is distinct from narcolepsy.
Effects of DM1 on splicing regulation result in
re-emergence of splice products that are normally
expressed at an earlier stage of development. More
specifically, in adult DM1 tissue there is inappropri-
ate expression of alternative splice isoforms that are
characteristic of late fetal or neonatal develop-
ment.2,3,6 In this regard, it is noteworthy that in-
creased REM sleep is typically seen in neonates.36
Based on results of the present study, it is possible
that EDS and increasedREMsleep inDM1does not
result from deficiency of Hcrt-1, but rather from re-
version to neonatal patterns of alternative splicing in
sleep regulatory circuits of the CNS, such as the
GABAergic flip-flop switch in the mesopontine teg-
mentum,35 resulting in partial recapitulation of neo-
natal sleep patterns.
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